肝硬化患者的门诊急性肾损伤常见且负担沉重
这项回顾性队列研究基于美国退伍军人事务部130家医院2018年1月1日至2019年12月31日诊断为肝硬化的55880例患者,中位随访3.4年,6889例(12%)发生门诊急性肾损伤(A-AKI)。腹水、MELD-Na>15、肝细胞癌和酒精相关肝病与A-AKI风险升高相关;42%的A-AKI事件未被识别,90天内60%缓解、4.5%进展至血液透析、12%死亡。
要点
- 肝硬化患者中12%发生门诊急性肾损伤,42%的事件未被识别。
- 腹水(OR 2.51)、MELD-Na>15(OR 1.58)、肝细胞癌(OR 1.45)、酒精相关肝病(OR 1.37)与A-AKI风险升高相关。
- A-AKI后90天内60%缓解、4.5%进展至血液透析、12%死亡。
核心结论
- 门诊急性肾损伤在肝硬化患者中常见,与90天高死亡率相关,且显著未被充分识别。
- 作者认为针对早期诊断和治疗的靶向干预可能改善高危患者的结局。
研究设计与样本
- 回顾性队列研究,纳入美国退伍军人事务部医疗系统130家医院2018年1月1日至2019年12月31日诊断为肝硬化的55880例患者。
- 以国际腹水俱乐部急性肾损伤标准在门诊环境中判定新发A-AKI,中位随访3.4年。
- 采用多变量回归模型识别肝硬化诊断后1年内发生A-AKI的相关因素,并对随机选取的250例A-AKI患者病历进行结构化隐式审查以确定诱因。
- 评估A-AKI后90天内的缓解率、血液透析率和死亡率。
主要发现
- 55880例肝硬化患者中位年龄66岁,38%为酒精相关肝硬化(酒精相关肝病),MELD-Na中位数10,34%有腹水。
- 6889例(12%)发生新发A-AKI。
- 腹水患者发生A-AKI的OR为2.51,MELD-Na>15为1.58,肝细胞癌为1.45,酒精相关肝病为1.37。
- A-AKI发生后90天内,60%缓解,4.5%进展至血液透析,12%死亡。
- 对250例随机选取的A-AKI患者病历审查显示,主要诱因为利尿剂和胃肠道丢失导致的低血容量以及肾毒性药物暴露;总体上42%的A-AKI事件未被识别。
关键数值与推荐
- A-AKI定义为在门诊环境中符合国际腹水俱乐部急性肾损伤标准。
- 发生A-AKI的相关因素:腹水OR 2.51,MELD-Na>15 OR 1.58,肝细胞癌OR 1.45,酒精相关肝病OR 1.37。
- A-AKI后90天结局:缓解60%,血液透析4.5%,死亡12%。
- 42%的A-AKI事件未被识别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about ambulatory acute kidney injury (A-AKI), which develops in an outpatient setting. METHODS: We conducted a retrospective cohort study of patients diagnosed with cirrhosis between January 1, 2018, and December 31, 2019 from 130 hospitals in the Veterans Affairs healthcare system. Patients were classified as having incident A-AKI if they met the International Club of Ascites AKI criteria in an outpatient setting. We used multivariable regression models to identify factors associated with A-AKI development within 1 year of cirrhosis diagnosis. We also conducted a structured implicit review of patients' medical charts to determine the precipitants of A-AKI. We examined the rates of AKI-resolution, hemodialysis and death at 90 days. RESULTS: Among 55,880 patients with cirrhosis [median age 66 years, 38% alcohol-related cirrhosis (alcohol-associated liver disease), median Model for End-Stage Liver Disease-Sodium 10, 34% ascites] followed for a median of 3.4 years, 6889 (12%) patients developed incident A-AKI. Patients with ascites (odds ratio [OR], 2.51), Model for End-Stage Liver Disease-Sodium >15 (OR, 1.58), hepatocellular carcinoma (OR, 1.45) or alcohol-associated liver disease (OR, 1.37) had higher odds of developing A-AKI. In total, 60% had AKI-resolution, 4.5% progressed to hemodialysis, and 12% died within 90 days of A-AKI onset. In a review of medical records of 250 randomly selected patients with A-AKI, key precipitants were hypovolemia due to diuretics and gastrointestinal losses, and nephrotoxin medication exposure. Overall, 42% of A-AKI events were unrecognized. CONCLUSIONS: A-AKI is common in cirrhosis, associated with high 90-day mortality, and significantly under-recognized. Targeted interventions for early diagnosis and treatment could improve outcomes in high-risk patients.
引用
- Patidar KR, Hernaez R, Liu Y, et al. Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome. Clin Gastroenterol Hepatol. 2025. PMID: 40354916. doi:10.1016/j.cgh.2025.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。